WO1985004811A1 - Bispecific antibody determinants - Google Patents
Bispecific antibody determinants Download PDFInfo
- Publication number
- WO1985004811A1 WO1985004811A1 PCT/US1985/000737 US8500737W WO8504811A1 WO 1985004811 A1 WO1985004811 A1 WO 1985004811A1 US 8500737 W US8500737 W US 8500737W WO 8504811 A1 WO8504811 A1 WO 8504811A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- molecules
- enzyme
- determinants
- wavelength
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
- G01N33/532—Production of labelled immunochemicals
- G01N33/533—Production of labelled immunochemicals with fluorescent label
Definitions
- the IgG antibodies are known to consist of two half-molecules, each consisting of a light (L) chain and a heavy (H) chain.
- the H chains of the two halves are linked by disulfide bonds, which can be broken by selective reduction. If this step is performed for two different IgG samples, the half-molecules can be combined to form hybrid antibodies. This has been accomplished using intact rabbit globulins; Nisonoff et al. (1964) Science 134, 376-379.
- the IgA antibodies can also be split into identical half-molecules.
- Hybrids have also been formed using the F(ab') 2 fragments of IgG antibodies, rather than intact antibodies; i.e., the F(c') portions of the molecules, which do not provide immunospecificity, are, prior to hybridization, removed by digestion with an appropriate protease such as pepsin.
- an appropriate protease such as pepsin.
- Hybrid antibodies have also been formed by fusing two cells, each capable of producing different antibodies, to make a hybrid cell capable of producing hybrid antibodies. Such a method is described in Milstein & Cuello (1983) Nature 305, 537-540. Mouse hybridoma cells producing different monoclonal antibodies was fused and the resulting fused cells produced mixtures of antibodies composed of all possible combinations of the two different sets of parental heavy and light chains. Among this mixture of molecules were hybrid antibodies consisting of one half of each of the parental antibody molecules, which could be partially purified by ion exchange chromatography. Another paper, Raso et al. (1981) Cancer
- the present invention provides a homogenous sample of identical bispecific antibody determinants, each bispecific determinant being composed of two L-H half-molecules linked by disulfide bonds, each L-H half-molecule being different from the other and being
- the bispecific monoclonal antibody determinants of the invention are made by providing two different monoclonal antibody determinants, each composed of two identical L-H half-molecules linked by one or more ⁇ ' ⁇ 5 disulfide bonds; subjecting the two different antibody determinants to conditions sufficient to break the disulfide bonds linking the L-H half-molecules under conditions which permit them to chemically combine to form the bispecific antibody determinants by the 0 formation of one or more disulfide bonds.
- the process further includes, prior to the combining step, derivatizing one pair of identical half-molecules with a thiol activating agent which facilitates the formation of the disulfide bonds 5 between the thiol activated half-molecules and the different half-molecules.
- a thiol activating agent which facilitates the formation of the disulfide bonds 5 between the thiol activated half-molecules and the different half-molecules.
- the monoclonal antibodies are IgG (most preferably IgG., or, less preferably, IgG2A, IgG2B, or IgG3) or IgA; each 0 half-molecule, if derived from an IgG antibody, includes at least the F(ab') portion; the thiol activating agent prevents the recombination of the thiol activated half-molecules; one or both of the monoclonal antibody determinants is composed of half-molecules linked by more than one disulfide bond, and the step of splitting such determinants into half-molecules is carried out under conditions which prevent the formation of disulfide bonds within the H chains of the half-molecules; and the thiol activating agent is 5,5'-dithiobis (2-nitrobenzoic acid), 2,2'-dipyridine disulfide, 4,4-dipyridine disulfide, or a mixture of sulfite and tetrathionate.
- IgG most
- disulfide bonds within the H chains of half-molecules originally linked by disulfide bonds is prevented by carrying out the splitting reaction in the presence of a dithiol complexing agent such as an arsenite, e.g., an inorganic arsenite such as sodium arsenite, or an aryl arsenite, e.g., phenylarsine oxide, or a cadminum salt, or by carrying out the splitting reaction under conditions under which the conformation of the H chains is modified to prevent disulfide bond formation, e.g., at a pH between 3.8 and 4.5 (most preferably 4.2), or by removing all but one reduced cysteine residue using a proteolytic enzyme such as carboxypeptidase Y.
- a dithiol complexing agent such as an arsenite, e.g., an inorganic arsenite such as sodium arsenite, or an aryl arsenite, e.g., phenylarsine oxide
- FIG. 1 is a diagrammatic representation of an assembly useful in a bioluminescence assay.
- Figure 2 is a diagrammatic representation of a channeling immunoassay employing bispecific monoclonal antioody determinants.
- Figure 3 is a diagrammatic representation of a fluorescent energy transfer immunoassay employing bispecific monoclonal antibody determinants.
- Figure 4 is a diagrammatic representation showing the structure of a rabbit IgG, compared to mouse IgG..
- Figure 5 is a diagrammatic representation of competing intrachain disulfide reactions in mouse half-molecules.
- Figure 6 is a diagrammatic representation of a preferred method of preparing bispecific monoclonal antibody determinants.
- Figure 7 is a diagrammatic representation of a luminescent energy transfer immunoassay employing bispecific monoclonal antibody determinants.
- the bispecific monoclonal antibody determinants of the invention are useful for a wide range of applications. These applications all flow from the ability of these determinants to serve as highly specific linkers through specific sites B 1 , of any two antigenic determinants capable of stimulating antibody production in animals; e.g., effective proteins, polypeptides, carbohydrates, nucleic acids, or haptens, either free or immobilized on surfaces or particles.
- One application of the bispecific antibody determinants of the invention is their use as agents for bonding a desired antigenic entity to a desired surface which contains or has immobilized on it a different antigenic determinant. For example, enzymes so immobilized on particles or membranes can be used as solid-state catalysts.
- bispecific antibody determinants can also be used as highly specific bispecific reagents for immunoassay procedures which are used, e.g., in the diagnosis of medical disorders, or as molecular probes to study the relationships between antigenic determinants in biological systems.
- bispecific antibody determinants are their use in electrodes.
- the invention can be used in electrodes of any configuration, e.g. in solid state sensors such as field effect transistors e.g., as described in Wohltjen (1984) Analyt. Chem. 5_6_, 87 .
- Enzyme electrodes made using bispecific antibody determinants possess several advantages over conventional enzyme electrodes.
- One advantage is their precise self-assembling property: the desired electrode assembly is generated simply by attaching the appropriate hapten or haptens to the membrane (either the electrode membrane or a separate membrane associated with the electrode) and then immersing the hapten-derived membrane into a solution containing the appropriate bispecific antibodies and enzymes.
- the electrode can be easily recharged after deterioration has occurred through prolonged use.
- Another advantage of the electrodes is also a function of the specificity of the bispecific antibody determinants. Any given enzyme will possess a number of antigenic sites capable of binding to a specific site of 5 an antibody. However, coupling at many of these sites can cause inactivation of the enzyme. In the case of bispecific monoclonal antibody determinants, this problem is avoided because the determinants are selected so that they couple with the enzyme only at a site which 10 does not cause deactivation of the enzyme.
- a further advantage is that assembly or recharging of the electrode can be done with impure enzyme mixtures because the unique specificity of the bispecific antibody determinants assures the selection of the proper enzymes from the impure mixture.
- the electrode assembly can be stabilized with a mild bifunctional cross linker, e.g., dimethyl suberimidate.
- antibody determinants are their use in the formation of self-assembling networks for use, e.g., as molecular microciruits.
- FIG. 4 illustrates the difference in structure between rabbit IgG. antibodies and mouse IgG. antibodies (which comprise most monoclonal antibodies.) These structures differ in the number of disulfide bonds linking the heavy chains. The two halves of rabbit IgG. are held together by a single bond, and the reduction of F(ab*)_ to F(ab') monomer as well as the reassociation of monomer to the dimer thus involves the breakage and reformation of only one bond, a relatively simple process. In contrast, the heavy chains of mouse IgG.
- the method of the invention allows the production of pure bispecific monoclonal antibody determinants in high yield, from mouse monoclonal antibodies as well as from antibodies derived from other mammalian species.
- the method involves the following sequence of steps. Using conventional methods, two different monoclonal IgG. antibody samples are produced, each antibody having one of two desired specificities. Each sample is then exposed to an appropriate protease such as pepsin to cleave off the F(c') portion of the antibody molecule to produce an F(ab')- > fragment.
- an appropriate protease such as pepsin
- Each sample is then subjected to conditions sufficient to break the disulfide bonds linking the F(ab') half-molecules, but not any of the other disulfide bonds in the molecule.
- these conditions are such as to prevent the formation of disulfides within a single heavy chain, for example by the addition of a dithiol complexing agent (e.g. sodium arsenite (as shown in Figure 6) , an aromatic arsenite such as phenylarsine oxide, or CdCl ⁇ ) , or by modifying the conformation of the heavy chain (e.g. by lowering the pH to 4.2), or by removing all but one of the reduced cysteine residues with a proteolytic enzyme (e.g.
- a dithiol complexing agent e.g. sodium arsenite (as shown in Figure 6) , an aromatic arsenite such as phenylarsine oxide, or CdCl ⁇
- a proteolytic enzyme e.g.
- carboxypeptidase Y carboxypeptidase Y
- a thiol-activating agent to complex all free thiols, forming a derivative that can react rapidly with other free thiols to form disulfides, as shown at the end of sequence 1 in Figure 6.
- agents suitable for this purpose are aromatic disulfides such as DTNB (Ellman (1959) Arch. Biochem. Biophys. 8_2, 70) ( Figure 6), 2,2'-dipyridine disulfide, 4,4'-dipyridine disulfide (Grasetti et al. (1967) Arch. Biochem. Biophys.
- both samples can be exposed to the thiol-activating agent to form the activated thiol derivatives. (This is frequently convenient because of the relatively good stability of the activated derivatives.)
- One of the samples is then treated with an excess of a low molecular weight thiol to regenerate the free thiols on the F(ab') monomer, followed by separation from excess low molecular thiols.
- Intramolecular disulfide bond formation can be avoided by the addition of a dithiol complexing agent (sequence 2 of Figure 6) or by modifying the conformation of the heavy chain. It may in some instances, however, be desirable to permit the formation of intramolecular disulfide bonds.
- This sample is then combined (sequence 3 of Figure 6) with the other F(ab') sample in the thiol-activated form under conditions where at least some half-molecules combine chemically to form 5 bispecific F(ab') 2 .
- the F(ab'') 2 fraction produced under those conditions consists only of the desired bispecific antibody determinants, provided appropriately purified monoclonal antibodies have been used as starting lOmaterials, homogenous bispecific antibody determinants can be obtained simply by removing the monomeric F(ab') fraction from the desired F(ab') 2 on the basis of molecular size, by a convenient procedure such as gel filtration.
- the first step is the preparation of monoclonal antibodies against the two proteins avidin and B-galactosidase. This is done by first immunizing one 5group of BALB/C mice against each enzyme using standard immunization procedures.
- spleen cells of immunized animals are prepared and fused with a derivative of MOPC-21 myeloma cells (e.g., NS1 or
- the hybrid cells are selected in hypoxanthine-aminopterin-thymidine medium, cloned, and screened for production of antibodies against the desired enzymes by the method described in Galfre et al. I_d.
- the clones found to produce antibodies against the desired enzyme are then screened to select a clone which produces an antibody of 5the IgG. class which has a high affinity for the enzyme and which does not cause inactivation of the enzyme.
- the clones of interest are stored until use under liquid nitrogen.
- Antibody is prepared by the standard technique of propagating the cloned cells as - ⁇ ascitic tumors in the peritoneal cavities of pristane-primed mice.
- the desired IgG. antibodies against avidin and B-galactosidase are then purified from ascites fluid essentially as described by Parham et al. (1982) Journal Immunological Methods J53_, 133-173, by a procedure involving ammonium sulfate precipitation, gel filtration, and chromatography on DEAE cellulose with a linear salt gradient.
- the monoclonal antibodies are cleaved to F(ab') 2 fragments with pepsin as described 2C by Lamoyi and Nisonoff (1983) Journal of Immunological Methods 56_, 235-243 by incubating for 18 hours at 25°C with pepsin (2% by weight) in 0.1 M sodium acetate, pH 4.2.
- the F(ab') 2 fragments are then purified by high performance liquid chromatography on a TSK 3000 SW
- the F(ab') 2 fractions are then completely converted to Fab 1 monomer by reduction with 1 mM 2-mercaptoethylamine in 1 mM EDTA, 10 mM sodium Q arsenite, and 0.1 M sodium phosphate, pH 6.8, for 18 hours at 25 C.
- the mixture is then supplemented with solid DTNB to final concentration of 20 mM.
- excess DTNB and low molecular weight products are removed by centrifugal gel filtration on Sephadex G-25 equilibrated with 0.1 M sodium phosphate, pH 6.8, and 1 mM EDTA.
- the resulting thionitrobenzoate derivatives of the Fab' monomers are relatively stable and can be stored for several days without significant decomposition.
- One of the thionitrobenzoate derivates of Fab' monomer (derived from the anti-avidin antibody) is then converted back to the free thiol form (complexed with dithiol) by incubating for 30 minutes at 25 C with 10 mM mercaptoethylamine in 1 mM EDTA, and 0.1 M sodium phosphate, pH 6.8. The excess mercaptoethylamine and low molecular weight reaction products are then removed D y centrifugal gel filtration on Sephadex G-25 equilibrated with 0.1 M sodium phosphate, pH 6.8, and 1 mM EDTA.
- the resulting anti-avidin F(ab') -thiol is then contacted immediately with an equimolar amount of the thionitrobenzoate derivative of the anti-B-galactosidase Fab', at a protein concentration of 0.5 mg/ml or higher, for 3-20 hours at 25 C, to allow formation of bispecific F(ab'),,.
- the mixture is then supplemented with solid DTNB to a final concentration of 5 mM and ieft for 3 hours at 25°C to promote dissipation of any non-covalent dimeric material.
- Homogenous bispecific antibody determinant against avidin and B-galactosidase is then prepared by separating the F(ab') fraction from residual Fab' monomers by high performance liquid chromatography on TSK 3000 SW in 0.1 M in sodium phosphate, pH 6.8, a procedure which does no damage to the F(ab') 2 , and does not require its being bonded to anything else, minimizing the risk for conformational changes which could affect activity.
- the formation of the desired bispecific antibody determinant can be conveniently demonstrated by its ability to cause the avidin-dependent binding of B-galactosidase to disks of biotin-substituted cellulose.
- the bispecific antibody determinant can be coupled to a biotin-substituted cellulose membrane in an assay for a compound, e.g., lactose, which B-galactosidase can help measure (as is explained in more detail below) .
- a compound e.g., lactose, which B-galactosidase can help measure (as is explained in more detail below) .
- Anti-B-galactosidase can be immobilized on the biotin substituted membrane by simply contacting the membrane (which has avidin bonded to the biotin) with the bispecific determinant having an anti-avidin half and an anti-B-galactosidase half, and with B-galactosidase. In a similar manner, glucose oxidase can be immobilized to the membrane.
- two bispecific molecules can be made, the first having specificity for a unique antigenic site on the enzyme glucose oxidase and for an antigenic site on B-galactosidase, and the second having specificity for a different antigenic site on glucose oxidase and for an antigenic site on Type I collagen. These can be used to form an electrode for measuring lactose generally, as described in Paulus, id.
- the following is a description of an example of the type of assay which employs the measurement of a substance which can be measured colorimetrically, reflectometrically, luminescently, or fluorometrically, as a measure of an unknown amount of a substance being assayed.
- the assay measures the amount of an unknown substance in a liquid sample, which substance is acted on by at least a first enzyme to evolve a measurable ion or compound which can be used as a measure of the unknown substance.
- the assay involves linking the first enzyme to a solid support (e.g.
- a bead or a membrane support of to a previously sequentially acting second enzyme, by means of a bispecific antibody determinant of the invention having specificity for the first enzyme and for the support or the second enzyme.
- a bispecific antibody determinant of the invention having specificity for the first enzyme and for the support or the second enzyme.
- sequential enzymes as are involved in the reaction sequence can be linked this way, with the last to act generally being linked to the support.
- the sample is contacted with the linked enzyme or enzymes immobilized on the support, and the measurable ion or compound is measured.
- Unknown substances which can be measured include, e.g., blood sugar.
- the sequential enzymes can be linked indirectly through an unknown substance to be measured through appropriate bispecific antibodies. This extends the range of substances that can be measured to biomolecules such as hormones (e.g., human chorionic gonadotropin, measured in pregnancy tests, and insulin) .
- hormones e.g., human chorionic gonadotropin, measured in pregnancy tests, and insulin
- Figure 1 illustrates an arrangement of self-assembling enzymes linked by bispecific antibody determinants (shown as chevrons linking circular enzymes) .
- the last enzyme in the sequence (luciferase) can be immobilized using, e.g. avidin and a biotin-substituted membrane (not shown) .
- Luciferase when reduced as shown, is bioluminescent (the reaction chain shown is described in greater detail in Wienhausen and DeLuca (1982) Anal. Biochem. 127, 380, and Hastings et al. U.S. Patent No. 4,278,761, hereby incorporated by reference) .
- Figure 2 illustrates a "channeling" immunoassay which employs two bispecific monoclonal antibody determinants.
- the illustrated assay employs some of the principles of the channeling immunoassay described in Litman et al. (1980) Anal. Biochem. 106, 223).
- the first bispecific determinant has specificity for a first enzyme and for a first antigenic site on an antigen being measured, e.g. human chorionic gonadotropin.
- the second bispecific determinant has specificity for a second enzyme and for a second antigenic site on the antigen being measured.
- the first enzyme is capable of acting on a first substrate to produce a second substrate which can be acted on by the second enzyme to evolve a measurable compound or ion.
- the assay is carried out by contacting the liquid mixture suspected of containing the molecule to be measured with the two bispecific determinants and the two enzymes, in the presence of the first substrate. If the unknown is present, the two determinants will bind to it and the two enzymes bound to them will be brought very close together, so that the efficiency of the two reactions is increased by orders of magnitude.
- the first enzyme is glucose oxidase
- the second enzyme is peroxidase
- the first substrate is glucose
- the second substrate is peroxide, which oxidizes a leukodye to produce a measurable dye.
- the last enzyme in the sequence can be immobilized.
- FIG. 2 includes an optical feature for improving the signal to noise ratio, the use of a competing enzyme (in this case, catalase) in an amount large enough to swamp the action of peroxidase in the absence of the enzyme-coupling unknown substance.
- Figure 3 illustrates a fluorescent energy transfer immunoassay analogous to the assay of Figure 2; the difference is that in the energy transfer assay, light, rather than organic substrates, is sequentially acted on to produce a measurable result.
- the assay employs two fluorescent proteins, in the illustrated assay, these are phycoerythrin ("Phy") and allophycocyanine (“All”) , both produced by blue-green algae and described, as being useful in immunoassays, in Glazer and Stryer (1983) Biophys. J.
- Phy phycoerythrin
- All allophycocyanine
- one bispecific monoclonal antibody determinant has specificity for a first site on the antigen being assayed (e.g. human cho ionic gonadotropin) and for Phy, and the second bispecific monoclonal antibody determinant has specificity for a second site on the antigen for All. Presence of the antigen closely couples Phy and All, greatly increasing energy transfer efficiency. The signal is produced because Phy excites at 500 nm and transmits at 580 nm, while All is transparent to 500 nm but excites at 580 nm and transmits at 660 nm.
- the 660 nm signal is only achieved by the sequential passage of light through both proteins, a process whose efficiency depends on proximity of the proteins.
- one or both fluorescent proteins can be immobilized on a support, either by conventional means or via bispecific determinants of the invention.
- a closely related type of immunoassay, illustrated in Figure 7, involves luminescence energy transfer between a luminescent molecule and a fluorescent substance, as in Patel et al. (1983) 5Analytical Biochemistry 129, 162-169.
- the luminescent protein aequorin is used in conjunction with phycoerythrin. The presence of the antigen closely couples aequorin and phycoerythrin, greatly increasing energy transfer efficiency.
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE8585902341T DE3583278D1 (en) | 1984-04-23 | 1985-04-22 | DOUBLE SPECIFIC ANTIBODY DETERMINANTS. |
JP60501961A JPH0617909B2 (en) | 1984-04-23 | 1985-04-22 | Bispecific antibody determinant |
AT85902341T ATE64622T1 (en) | 1984-04-23 | 1985-04-22 | DOUBLE SPECIFIC ANTIBODY DETERMINANTS. |
FI855086A FI85946C (en) | 1984-04-23 | 1985-12-19 | Process for producing a bispecific antibody and assay method using it |
NO85855200A NO166383C (en) | 1984-04-23 | 1985-12-20 | PROCEDURE FOR MANUFACTURING BISPECIFIC ANTIBODY DETERMINANTS. |
DK601985A DK169153B1 (en) | 1984-04-23 | 1985-12-23 | Process for preparing a bispecific monoclonal antibody determinant |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60312584A | 1984-04-23 | 1984-04-23 | |
US603,125 | 1984-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1985004811A1 true WO1985004811A1 (en) | 1985-11-07 |
Family
ID=24414191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1985/000737 WO1985004811A1 (en) | 1984-04-23 | 1985-04-22 | Bispecific antibody determinants |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0179872B1 (en) |
JP (1) | JPH0617909B2 (en) |
AT (1) | ATE64622T1 (en) |
AU (1) | AU595159B2 (en) |
CA (1) | CA1338828C (en) |
DE (1) | DE3583278D1 (en) |
DK (1) | DK169153B1 (en) |
FI (1) | FI85946C (en) |
IT (1) | IT1183798B (en) |
NO (1) | NO166383C (en) |
WO (1) | WO1985004811A1 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987004164A1 (en) * | 1986-01-06 | 1987-07-16 | The University Of Melbourne | Technetium-antibody conjugate |
US4796889A (en) * | 1986-12-19 | 1989-01-10 | Renaud Muraour | Tip for tennis racket handle and the like, and racket equipped with this tip |
EP0301333A2 (en) * | 1987-07-29 | 1989-02-01 | Abbott Laboratories | Liposome based homogeneous immunoassay for diagnostic tests |
EP0308242A2 (en) * | 1987-09-17 | 1989-03-22 | Agen Limited | Agglutination assay |
EP0336379A2 (en) * | 1988-04-04 | 1989-10-11 | Oncogen Limited Partnership | Antibody heteroconjugates for use in regulation of lymphocyte activity |
WO1990005305A1 (en) * | 1988-11-10 | 1990-05-17 | Pharmacia Ab | Surface plasmon resonance sensor unit and its use in biosensor systems |
WO1990007714A1 (en) * | 1988-12-23 | 1990-07-12 | Applied Research Systems Ars Holding N.V. | Homogeneous encym immunoassay |
US4971916A (en) * | 1987-07-29 | 1990-11-20 | Abbott Laboratories | Liposome based homogeneous immunoassay for diagnostic tests |
EP0450479A1 (en) * | 1990-04-02 | 1991-10-09 | Takeda Chemical Industries, Ltd. | Bispecific monoclonal anti-bodies, their production and use |
US5086002A (en) * | 1987-09-07 | 1992-02-04 | Agen Biomedical, Ltd. | Erythrocyte agglutination assay |
US5256395A (en) * | 1986-09-19 | 1993-10-26 | Immunotech Partners | Affinity enhancement immunological reagents for in vivo detection and killing of specific target cells |
US6010902A (en) * | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5583003A (en) * | 1989-09-25 | 1996-12-10 | Agen Limited | Agglutination assay |
EP2064549B1 (en) * | 2006-09-21 | 2012-10-24 | Prometheus Laboratories, Inc. | Antibody-based arrays for detecting multiple signal transducers in rare circulating cells |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4233402A (en) * | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
WO1983003679A1 (en) * | 1982-04-12 | 1983-10-27 | Hybritech Inc | Antibodies having dual specificities, their preparation and uses therefor |
US4433059A (en) * | 1981-09-08 | 1984-02-21 | Ortho Diagnostic Systems Inc. | Double antibody conjugate |
US4446233A (en) * | 1982-05-05 | 1984-05-01 | E. I. Du Pont De Nemours And Company | Homogeneous immunoassay using covalent hybrid antibodies |
US4470925A (en) * | 1982-05-05 | 1984-09-11 | E. I. Du Pont De Nemours And Company | Immunoglobulin half-molecules and process for producing hybrid antibodies |
US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4520110A (en) * | 1981-10-06 | 1985-05-28 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing a phycobiliprotein labeled ligand or receptor |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU531777B2 (en) * | 1978-04-05 | 1983-09-08 | Syva Co. | Label/solid conjugate immunoassay system |
US4433859A (en) * | 1981-07-16 | 1984-02-28 | Nl Industries, Inc. | Wellhead connector with release mechanism |
DE3262442D1 (en) * | 1981-10-06 | 1985-03-28 | Univ Leland Stanford Junior | Fluorescent conjugates for analysis of molecules and cells |
CA1194415A (en) * | 1982-05-05 | 1985-10-01 | E. I. Du Pont De Nemours And Company | Immunoglobulin half-molecules and process for producing hybrid antibodies |
-
1985
- 1985-04-22 AU AU42901/85A patent/AU595159B2/en not_active Expired
- 1985-04-22 AT AT85902341T patent/ATE64622T1/en not_active IP Right Cessation
- 1985-04-22 JP JP60501961A patent/JPH0617909B2/en not_active Expired - Lifetime
- 1985-04-22 WO PCT/US1985/000737 patent/WO1985004811A1/en active IP Right Grant
- 1985-04-22 DE DE8585902341T patent/DE3583278D1/en not_active Expired - Lifetime
- 1985-04-22 EP EP85902341A patent/EP0179872B1/en not_active Expired - Lifetime
- 1985-04-23 CA CA000479784A patent/CA1338828C/en not_active Expired - Fee Related
- 1985-04-23 IT IT67383/85A patent/IT1183798B/en active
- 1985-12-19 FI FI855086A patent/FI85946C/en not_active IP Right Cessation
- 1985-12-20 NO NO85855200A patent/NO166383C/en unknown
- 1985-12-23 DK DK601985A patent/DK169153B1/en not_active IP Right Cessation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4233402A (en) * | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
US4474893A (en) * | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4433059A (en) * | 1981-09-08 | 1984-02-21 | Ortho Diagnostic Systems Inc. | Double antibody conjugate |
US4520110A (en) * | 1981-10-06 | 1985-05-28 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing a phycobiliprotein labeled ligand or receptor |
WO1983003679A1 (en) * | 1982-04-12 | 1983-10-27 | Hybritech Inc | Antibodies having dual specificities, their preparation and uses therefor |
US4446233A (en) * | 1982-05-05 | 1984-05-01 | E. I. Du Pont De Nemours And Company | Homogeneous immunoassay using covalent hybrid antibodies |
US4470925A (en) * | 1982-05-05 | 1984-09-11 | E. I. Du Pont De Nemours And Company | Immunoglobulin half-molecules and process for producing hybrid antibodies |
Non-Patent Citations (4)
Title |
---|
Journal of Experimental Medicine, 128, issued 1968, HAMMERLING et al, 1461-1469 * |
Journal of Immunological Methods, 56, issued 1983, LAMOYI et al, 235-245 * |
See also references of EP0179872A4 * |
The Journal of Immunology, 125(6), issued 1980, RASO et al, 2610-2616 * |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1987004164A1 (en) * | 1986-01-06 | 1987-07-16 | The University Of Melbourne | Technetium-antibody conjugate |
US5256395A (en) * | 1986-09-19 | 1993-10-26 | Immunotech Partners | Affinity enhancement immunological reagents for in vivo detection and killing of specific target cells |
US4796889A (en) * | 1986-12-19 | 1989-01-10 | Renaud Muraour | Tip for tennis racket handle and the like, and racket equipped with this tip |
EP0301333A2 (en) * | 1987-07-29 | 1989-02-01 | Abbott Laboratories | Liposome based homogeneous immunoassay for diagnostic tests |
EP0301333A3 (en) * | 1987-07-29 | 1992-07-01 | Abbott Laboratories | Liposome based homogeneous immunoassay for diagnostic tests |
US4971916A (en) * | 1987-07-29 | 1990-11-20 | Abbott Laboratories | Liposome based homogeneous immunoassay for diagnostic tests |
US5413913A (en) * | 1987-09-07 | 1995-05-09 | Agen Biomedical, Ltd. | Erythrocyte agglutination assay |
US5086002A (en) * | 1987-09-07 | 1992-02-04 | Agen Biomedical, Ltd. | Erythrocyte agglutination assay |
EP0308242A3 (en) * | 1987-09-17 | 1990-10-10 | Agen Limited | Agglutination assay |
EP0308242A2 (en) * | 1987-09-17 | 1989-03-22 | Agen Limited | Agglutination assay |
EP0336379A3 (en) * | 1988-04-04 | 1990-01-31 | Oncogen Ltd. | Antibody heteroconjugates for use in regulation of lymphocyte activity |
EP0336379A2 (en) * | 1988-04-04 | 1989-10-11 | Oncogen Limited Partnership | Antibody heteroconjugates for use in regulation of lymphocyte activity |
US6010902A (en) * | 1988-04-04 | 2000-01-04 | Bristol-Meyers Squibb Company | Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity |
WO1990005305A1 (en) * | 1988-11-10 | 1990-05-17 | Pharmacia Ab | Surface plasmon resonance sensor unit and its use in biosensor systems |
US5492840A (en) * | 1988-11-10 | 1996-02-20 | Pharmacia Biosensor Ab | Surface plasmon resonance sensor unit and its use in biosensor systems |
WO1990007714A1 (en) * | 1988-12-23 | 1990-07-12 | Applied Research Systems Ars Holding N.V. | Homogeneous encym immunoassay |
US5415998A (en) * | 1988-12-23 | 1995-05-16 | Applied Research Systems Ars Holding N.V. | Enzyme-containing quaternary immunocomplex homogeneous assay |
EP0450479A1 (en) * | 1990-04-02 | 1991-10-09 | Takeda Chemical Industries, Ltd. | Bispecific monoclonal anti-bodies, their production and use |
Also Published As
Publication number | Publication date |
---|---|
JPH0617909B2 (en) | 1994-03-09 |
ATE64622T1 (en) | 1991-07-15 |
JPS61501418A (en) | 1986-07-10 |
IT8567383A0 (en) | 1985-04-23 |
EP0179872A1 (en) | 1986-05-07 |
NO855200L (en) | 1985-12-20 |
CA1338828C (en) | 1997-01-07 |
FI85946C (en) | 1992-06-25 |
DE3583278D1 (en) | 1991-07-25 |
DK169153B1 (en) | 1994-08-29 |
IT1183798B (en) | 1987-10-22 |
FI85946B (en) | 1992-03-13 |
EP0179872A4 (en) | 1988-12-22 |
DK601985A (en) | 1985-12-23 |
EP0179872B1 (en) | 1991-06-19 |
AU4290185A (en) | 1985-11-15 |
NO166383C (en) | 1991-07-10 |
IT8567383A1 (en) | 1986-10-23 |
DK601985D0 (en) | 1985-12-23 |
NO166383B (en) | 1991-04-02 |
FI855086A0 (en) | 1985-12-19 |
AU595159B2 (en) | 1990-03-29 |
FI855086A (en) | 1985-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5523210A (en) | Bispecific antibody determinants | |
US4444878A (en) | Bispecific antibody determinants | |
EP0179872B1 (en) | Bispecific antibody determinants | |
US4470925A (en) | Immunoglobulin half-molecules and process for producing hybrid antibodies | |
US4479895A (en) | Immunoglobulin half-molecules and process for producing hybrid antibodies | |
JPH0753600A (en) | Hybrid monoclonal antibody with double specificity | |
JPS58203919A (en) | Manufacture of immunogloblin half molecule and crossbred antibody | |
JPH01114758A (en) | Manufacture of antibody fragment preparation containing no papain | |
JPH0322946B2 (en) | ||
GB2098730A (en) | Immunolocalisation | |
CA1186622A (en) | Homogeneous immunoassay with labeled monoclonal anti- analyte | |
CA1194415A (en) | Immunoglobulin half-molecules and process for producing hybrid antibodies | |
Crofton | Site of alkaline phosphatase attachment in alkaline phosphatase-immunoglobulin G complexes | |
JPS6149624B2 (en) | ||
JPH07122622B2 (en) | Immunosensor | |
US4942136A (en) | Method for production of fluorescence-labeled Fab' | |
JPH0276899A (en) | Production of bi-specific antibody | |
JPH0283398A (en) | Synthetic peptide and measuring kid and measuring method of human mn-superoxide dismutase using the same peptide | |
JPH0799369B2 (en) | Enzyme immunoassay for epidermal growth factor | |
JPH021555A (en) | Immunological measurement of human protein s and measurement reagent and kit used therefor | |
JPS63117264A (en) | Measurement of antigen | |
JPS613065A (en) | Measurement of antigen | |
JPH0466870A (en) | Novel labeling body and immunoassay using the same | |
JPH0731200B2 (en) | Method for producing catalase-labeled antibody | |
JPH04216467A (en) | Immunoassay |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU DK FI JP NO Designated state(s): AU DK FI JP NO |
|
AL | Designated countries for regional patents |
Designated state(s): AT BE CH DE FR GB IT LU NL SE Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 855086 Country of ref document: FI |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1985902341 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1985902341 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1985902341 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 855086 Country of ref document: FI |